BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH

424 General Military Hospital

Status: Completed

Conditions: Muscle; Bone Metabolism; Endometriosis; Bone Density

Treatments: Drug: Goserelin Acetate

Study type: Observational

Funder types: Other

Identifiers

NCT04203212

Menomyobone

Details and patient eligibility

About

The investigators aim to investigate the effect of menstrual cessation in women with endometriosis treated with GnRH analogs for 6 months on bone mineral density and bone and muscle metabolism parameters and subsequently the effects of menstrual restoration after GnRH analogs discontinuation on the above measured parameters

Full description

Prospective, open-label, controlled 12month observational study

Premenopausal women with surgically verified endometriosis will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration. Age- and BMI-matched premenopausal, health women will serve as controls. Controls will receive no treatment.

Enrollment: 41 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Premenopausal women with surgically verified endometriosis

Exclusion criteria

1. Secondary osteoporosis
2. diseases or conditions that could affect bone and/or muscle metabolism
3. any medications that could affect bone and/or muscle metabolism

Trial design

41 participants in 2 patient groups

Endometriosis Group

Description:

20 premenopausal women with surgically verified endometriosis who will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration.

Treatment:

Drug: Goserelin Acetate

Control Group

Description:

20 age- and BMI-matched premenopausal, health women who will receive no treatment and be monitored for 6 months.